ArticleBMC cancer2025
Impact of ovarian function suppression on prognosis in premenopausal patients with HR+/HER2 + early-stage breast cancer: a multi-center retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Early Breast Cancer: A Comprehensive Review.Journal of breast cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe impact of adjuvant ovarian function suppression (OFS) in premenopausal patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) breast cancer remains unclear. The study aims to evaluate the value of OFS for patients with HR+/HER2 + early-stage breast cancer treated with trastuzumab.
methodsKaplan-Meier curves and the log-rank test were used to compare disease-free survival (DFS). Univariate and multivariate Cox regression analyses were performed to identify significant prognostic factors. Multivariable logistic regression model was used to predict the utilization of OFS.
resultsA total of 1,338 patients from multiple centers were enrolled, including 570 who received OFS treatment. Patients treated with selective estrogen receptor modulators (SERM) or aromatase inhibitors (AI) plus OFS as adjuvant endocrine therapy showed significantly better DFS compared to those who received SERM alone (HR = 0.496; 95% CI: 0.307-0.803; p = 0.004). Univariate and multivariate Cox regression analysis further confirmed that receiving SERM/AI plus OFS as adjuvant endocrine therapy was an independent prognostic factor in HR+/HER2 + early-stage breast cancer patients. Subgroup analysis indicated that patients with estrogen-receptor (ER) expression below 50%, histological grade 3, tumors larger than 2 cm, or lymph node-positive could benefit from OFS. In addition, age<35 years, nodal involvement, histological grade 3 and ER expression below 50% were more likely to receive OFS compared with control group.
conclusionOur study confirms that premenopausal patients with HR+/HER2 + early-stage breast cancer could benefit from additional OFS after trastuzumab treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.